There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opiant Pharmaceuticals (OPNT) and Biodesix (BDSX) with bullish sentiments.
Opiant Pharmaceuticals (OPNT)
Northland Securities analyst Carl Byrnes maintained a Buy rating on Opiant Pharmaceuticals today and set a price target of $42.00. The company’s shares closed last Thursday at $8.40.
According to TipRanks.com, Byrnes is ranked 0 out of 5 stars with an average return of -10.4% and a 34.1% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Aridis Pharmaceuticals, and Flexion Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Opiant Pharmaceuticals with a $42.00 average price target.
See today’s analyst top recommended stocks >>
Biodesix (BDSX)
Canaccord Genuity analyst Max Masucci maintained a Buy rating on Biodesix yesterday and set a price target of $26.00. The company’s shares closed last Thursday at $15.69.
According to TipRanks.com, Masucci is a 5-star analyst with an average return of 63.5% and a 80.0% success rate. Masucci covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Genetron Holdings, and Guardant Health.
Biodesix has an analyst consensus of Strong Buy, with a price target consensus of $22.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
